Azam Shafaei

Mrs. Azam Shafaei


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2023 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MRMasooma Rahimzada
Masooma Rahimzada
MNMehri Nahavandi
Mehri Nahavandi
MSMona Saffari
Mona Saffari
ASAzam Shafaei
Azam Shafaei
AMArman Mosavat
Arman Mosavat
MDMohammad Derakhshan
Mohammad Derakhshan

Verified
Journal Article
Open access
PDF file
MSMaryam Shahi
Maryam Shahi
ASAzam Shafaei
Azam Shafaei
MGMohamad Ghodsi
Mohamad Ghodsi
REReza Jafarzadeh Esfehani
Reza Jafarzadeh Esfehani
MMMahdi Moradi Marjaneh
Mahdi Moradi Marjaneh
Introduction: Human papillomavirus (HPV) genotyping is critical for preventing and managing HPV-related health issues, including cancers. This study re-evaluates HPV genotype trends in Iran to inform prevention strategies. Materials and Methods: A cross-sectional analysis of HPV genotyping data from individuals tested at the ACECR Khorasan Razavi molecular laboratory in Iran (2016–2022) was conducted, with a forecast of genotype trends through 2027. Results: Among 5009 female patients, 40.4% tested positive for HPV (mean age: 32 ± 8.77 years), with a significant upward trend in positivity over time (tau = 0.905, p = 0.0069). HPV 6, 11, 16, 31, 53, and 54 showed significant increases (p < 0.01), while HPV 66, 84, 67, and 35 exhibited notable trends (p < 0.05). HPV 18 and 33 had marginal trends (p = 0.065, p = 0.052), and HPV 68, 70, and 82 remained stable. Linear regression indicated a non-significant decline in low-risk HPV cases (R = 0.703, p = 0.078) and negligible change in high-risk cases (R = 0.052, p = 0.912). Forecasts predicted increases in HPV 84, 54, 43, 42, and 26, with HPV 6 projected to decrease significantly. HPV 44, 73, and 33 were expected to remain stable. Conclusion: While low-risk HPV cases may decline, the trend lacks statistical significance, and high-risk HPV cases show no change. These findings underscore the need for targeted prevention strategies in Iran, particularly for high-risk genotypes, to reduce the burden of HPV-related cancers. Further research is essential to validate these trends and refine public health interventions.